Mendelian disorders of high-density lipoprotein metabolism

Circulation Research

Volumn 114, Issue 1, 2014, Pages 124-142

  Oldoni, Federico ^a   Sinke, Richard J ^a   Kuivenhoven, Jan Albert ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

cholesterol; high density lipoprotein; lipoproteins

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ANGIOPOIETIN; ANGIOPOIETIN LIKE 3; ANGIOPOIETIN LIKE 4; APOLIPOPROTEIN A1; APOLIPOPROTEIN A5; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN M; BINDING PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE; ENDOTHELIAL LIPASE; EPIMERASE; GLUCOSYLCERAMIDASE; GLUCURONIC ACID EPIMERASE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED HDL BINDING PROTEIN 1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; N ACETYLGALACTOSAMINYLTRANSFERASE; N ACETYLGALACTOSAMINYLTRANSFERASE 2; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPASE A2; PHOSPHOLIPID TRANSFER PROTEIN; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISORDERS OF LIPOPROTEIN METABOLISM; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HOMEOSTASIS; HUMAN; HYPERALPHALIPOPROTEINEMIA; HYPOALPHALIPOPROTEINEMIA; LIPID METABOLISM; LIPOLYSIS; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; LOSS OF FUNCTION MUTATION; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

EID: 84892977223     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.113.300634     Document Type: Review

References (279)

1. Scriver RG, Sly WS, Childs B, Beaudet AL, Valle D, Kinzler KW, Bert Vogelstein B, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001.
2. Serfaty-Lacrosniere C, Civeira F, Lanzberg A, Isaia P, Berg J, Janus ED, Smith MP Jr, Pritchard PH, Frohlich J, Lees RS. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis. 1994;107:85-98.
3. Clee SM, Kastelein JJ, van Dam M, et al. Age and residual cholesterol ef-fux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest. 2000;106:1263-1270.
4. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Steffensen R, Tybjaerg-Hansen A. Genetic variation in ABCA1 predicts ischemic heart disease in the general population. Arterioscler Thromb Vasc Biol. 2008;28:180-186.
5. Zwarts KY, Clee SM, Zwinderman AH, Engert JC, Singaraja R, Loubser O, James E, Roomp K, Hudson TJ, Jukema JW, Kastelein JJ, Hayden MR. ABCA1 regulatory variants infuence coronary artery disease independent of effects on plasma lipid levels. Clin Genet. 2002;61:115-125.
6. Orsó E, Broccardo C, Kaminski WE, et al. Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-defcient mice. Nat Genet. 2000;24:192-196.
7. Christiansen-Weber TA, Voland JR, Wu Y, Ngo K, Roland BL, Nguyen S, Peterson PA, Fung-Leung WP. Functional loss of ABCA1 in mice causes severe placental malformation, aberrant lipid distribution, and kidney glo-merulonephritis as well as high-density lipoprotein cholesterol defciency. Am J Pathol. 2000;157:1017-1029.
8. Groen AK, Bloks VW, Bandsma RH, Ottenhoff R, Chimini G, Kuipers F. Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL. J Clin Invest. 2001;108:843-850.
9. Aiello RJ, Brees D, Bourassa PA, Royer L, Lindsey S, Coskran T, Haghpassand M, Francone OL. Increased atherosclerosis in hyperlip-idemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol. 2002;22:630-637.
10. Ragozin S, Niemeier A, Laatsch A, Loeffer B, Merkel M, Beisiegel U, Heeren J. Knockdown of hepatic ABCA1 by RNA interference decreases plasma HDL cholesterol levels and infuences postprandial lipemia in mice. Arterioscler Thromb Vasc Biol. 2005;25:1433-1438.
11. Joyce C, Freeman L, Brewer HB Jr, Santamarina-Fojo S. Study of ABCA1 function in transgenic mice. Arterioscler Thromb Vasc Biol. 2003;23:965-971.
12. Joyce CW, Wagner EM, Basso F, et al. ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis. J Biol Chem. 2006;281:33053-33065.
13. Singaraja RR, Fievet C, Castro G, James ER, Hennuyer N, Clee SM, Bissada N, Choy JC, Fruchart JC, McManus BM, Staels B, Hayden MR. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest. 2002;110:35-42.
14. Van Eck M, Singaraja RR, Ye D, Hildebrand RB, James ER, Hayden MR, Van Berkel TJ. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2006;26:929-934.
15. Abellán R, Mansego ML, Martínez-Hervás S, Martín-Escudero JC, Carmena R, Real JT, Redon J, Castrodeza-Sanz JJ, Chaves FJ. Association of selected ABC gene family single nucleotide polymorphisms with postprandial lipoproteins: results from the population-based Hortega study. Atherosclerosis. 2010;211:203-209.
16. Furuyama S, Uehara Y, Zhang B, Baba Y, Abe S, Iwamoto T, Miura S, Saku K. Genotypic Effect of ABCG1 gene promoter-257TG polymorphism on coronary artery disease severity in Japanese men. J Atheroscler Thromb. 2009;16:194-200.
17. Xu Y, Wang W, Zhang L, Qi LP, Li LY, Chen LF, Fang Q, Dang AM, Yan XW. A polymorphism in the ABCG1 promoter is functionally associated with coronary artery disease in a Chinese Han population. Atherosclerosis. 2011;219:648-654.
18. Kennedy MA, Barrera GC, Nakamura K, Baldán A, Tarr P, Fishbein MC, Frank J, Francone OL, Edwards PA. ABCG1 has a critical role in mediating cholesterol effux to HDL and preventing cellular lipid accumulation. Cell Metab. 2005;1:121-131.
19. Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, Welch C, Tall AR. Combined defciency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest. 2007;117:3900-3908.
20. Westerterp M, Koetsveld J, Yu S, Han S, Li R, Goldberg IJ, Welch CL, Tall AR. Increased atherosclerosis in mice with vascular ATP-binding cassette transporter G1 defciency-brief report. Arterioscler Thromb Vasc Biol. 2010;30:2103-2105.
21. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol effux to high-density lipoproteins. Proc Natl Acad Sci USA. 2004;101:9774-9779.
22. Wada M, Iso T, Asztalos BF, Takama N, Nakajima T, Seta Y, Kaneko K, Taniguchi Y, Kobayashi H, Nakajima K, Schaefer EJ, Kurabayashi M. Marked high density lipoprotein defciency due to apolipoprotein A-I Tomioka (codon 138 deletion). Atherosclerosis. 2009;207:157-161.
23. Norum RA, Lakier JB, Goldstein S, Angel A, Goldberg RB, Block WD, Noffze DK, Dolphin PJ, Edelglass J, Bogorad DD, Alaupovic P. Familial defciency of apolipoproteins A-I and C-III and precocious coronary-artery disease. N Engl J Med. 1982;306:1513-1519.
24. Franceschini G, Sirtori CR, Capurso A 2nd, Weisgraber KH, Mahley RW. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with signifcant lipoprotein modifcations and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980;66:892-900.
25. Brown CM, Rea TJ, Hamon SC, Hixson JE, Boerwinkle E, Clark AG, Sing CF. The contribution of individual and pairwise combinations of SNPs in the APOA1 and APOC3 genes to interindividual HDL-C variability. J Mol Med (Berl). 2006;84:561-572.
26. Moore RE, Kawashiri MA, Kitajima K, Secreto A, Millar JS, Pratico D, Rader DJ. Apolipoprotein A-I defciency results in markedly increased atherosclerosis in mice lacking the LDL receptor. Arterioscler Thromb Vasc Biol. 2003;23:1914-1920.
27. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003;108:661-663.
28. Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res. 2010;51:2058-2073.
29. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-267.
30. Bi N, Yan SK, Li GP, Yin ZN, Chen BS. A single nucleotide polymorphism-1131TC in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and alters triglyceride metabolism in Chinese. Mol Genet Metab. 2004;83:280-286.
31. Liu H, Zhang S, Lin J, Li H, Huang A, Xiao C, Li X, Su Z, Wang C, Nebert DW, Zhou B, Zheng K, Shi J, Li G, Huang D. Association between DNA variant sites in the apolipoprotein A5 gene and coronary heart disease in Chinese. Metabolism. 2005;54:568-572.
32. Boes E, Coassin S, Kollerits B, Heid IM, Kronenberg F. Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review. Exp Gerontol. 2009;44:136-160.
33. Lookene A, Beckstead JA, Nilsson S, Olivecrona G, Ryan RO. Apolipoprotein A-V-heparin interactions: implications for plasma lipopro-tein metabolism. J Biol Chem. 2005;280:25383-25387.
34. Nilsson SK, Lookene A, Beckstead JA, Gliemann J, Ryan RO, Olivecrona G. Apolipoprotein A-V interaction with members of the low density lipo-protein receptor gene family. Biochemistry. 2007;46:3896-3904.
35. Priore Oliva C, Pisciotta L, Li Volti G, Sambataro MP, Cantafora A, Bellocchio A, Catapano A, Tarugi P, Bertolini S, Calandra S. Inherited apo-lipoprotein A-V defciency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2005;25:411-417.
36. Weissglas-Volkov D, Aguilar-Salinas CA, Sinsheimer JS, Riba L, Huertas-Vazquez A, Ordoñez-Sánchez ML, Rodriguez-Guillen R, Cantor RM, Tusie-Luna T, Pajukanta P. Investigation of variants identifed in caucasian genome-wide association studies for plasma high-density lipoprotein cholesterol and triglycerides levels in Mexican dyslipidemic study samples. Circ Cardiovasc Genet. 2010;3:31-38.
37. Priore Oliva C, Carubbi F, Schaap FG, Bertolini S, Calandra S. Hypertriglyceridaemia and low plasma HDL in a patient with apolipopro-tein A-V defciency due to a novel mutation in the APOA5 gene. J Intern Med. 2008;263:450-458.
38. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein infuencing triglycer-ides in humans and mice revealed by comparative sequencing. Science. 2001;294:169-173.
39. Gerber Y, Goldbourt U, Cohen H, Harats D. Association between serum apolipoprotein C(II) concentration and coronary heart disease. Prev Med. 2002;35:42-47.
40. Johansen CT, Wang J, McIntyre AD, et al. Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertri-glyceridemia. Circ Cardiovasc Genet. 2012;5:66-72.
41. Takase S, Osuga J, Fujita H, et al. Apolipoprotein C-II defciency with no rare variant in the APOC2 gene. J Atheroscler Thromb. 2013;20:481-493.
42. Shachter NS, Hayek T, Leff T, Smith JD, Rosenberg DW, Walsh A, Ramakrishnan R, Goldberg IJ, Ginsberg HN, Breslow JL. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest. 1994;93:1683-1690.
43. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR. A null mutation in human APOC3 confers a favorable plasma lipid profle and apparent cardioprotection. Science. 2008;322:1702-1705.
44. Gerritsen G, Rensen PC, Kypreos KE, Zannis VI, Havekes LM, Willems van Dijk K. ApoC-III defciency prevents hyperlipidemia induced by apoE overexpression. J Lipid Res. 2005;46:1466-1473.
45. Hofker MH. APOC3 null mutation affects lipoprotein profle APOC3 def-ciency: from mice to man. Eur J Hum Genet. 2010;18:1-2.
46. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 1999;19:472-484.
47. Qu S, Perdomo G, Su D, D'Souza FM, Shachter NS, Dong HH. Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice. J Lipid Res. 2007;48:1476-1487.
48. Bobik A. Apolipoprotein CIII and atherosclerosis: beyond effects on lipid metabolism. Circulation. 2008;118:702-704.
49. Ahnström J, Axler O, Jauhiainen M, Salomaa V, Havulinna AS, Ehnholm C, Frikke-Schmidt R, Tybjaerg-Hansen A, Dahlbäck B. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. J Lipid Res. 2008;49:1912-1917.
50. Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol effux to HDL and protects against atherosclerosis. Nat Med. 2005;11:418-422.
51. Christoffersen C, Jauhiainen M, Moser M, Porse B, Ehnholm C, Boesl M, Dahlbäck B, Nielsen LB. Effect of apolipoprotein M on high density lipo-protein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem. 2008;283:1839-1847.
52. Kral BG, Becker DM. Familial occurrence of abnormalities of high-density lipoprotein cholesterol. J Clin Lipidol. 2007;1:31-40.
53. Ishigami M, Yamashita S, Sakai N, Arai T, Hirano K, Hiraoka H, Kameda-Takemura K, Matsuzawa Y. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) defciency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem. 1994;116:257-262.
54. Boekholdt SM, Kuivenhoven JA, Hovingh GK, Jukema JW, Kastelein JJ, van Tol A. CETP gene variation: relation to lipid parameters and cardiovascular risk. Curr Opin Lipidol. 2004;15:393-398.
55. Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and effcacy of pravastatin treatment: individual patient meta-analysis of 13, 677 subjects. Circulation. 2005;111:278-287.
56. Huang Z, Inazu A, Kawashiri MA, Nohara A, Higashikata T, Mabuchi H. Dual effects on HDL metabolism by cholesteryl ester transfer protein inhibition in HepG2 cells. Am J Physiol Endocrinol Metab. 2003;284:E1210-E1219.
57. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, Tall AR. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest. 1995;96:2071-2074.
58. Foger B, Vaisman BL, Paigen B, Hoyt RF Jr, Brewer HB Jr, Santamarina-Fojo S. CETP modulates the development of aortic atherosclerosis in LCAT transgenic mice. Circulation. 1997;96:II-1-II-6.
59. Tietjen I, Hovingh GK, Singaraja RR, Radomski C, Barhdadi A, McEwen J, Chan E, Mattice M, Legendre A, Franchini PL, Dubé MP, Kastelein JJ, Hayden MR. Segregation of LIPG, CETP, and GALNT2 mutations in Caucasian families with extremely high HDL cholesterol. PLoS One. 2012;7:e37437.
60. Holleboom AG, Karlsson H, Lin RS, et al. Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. Cell Metab. 2011;14:811-818.
61. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707-713.
62. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) defciency syndromes. J Lipid Res. 1997;38:191-205.
63. Hovingh GK, Hutten BA, Holleboom AG, Petersen W, Rol P, Stalenhoef A, Zwinderman AH, de Groot E, Kastelein JJ, Kuivenhoven JA. Compromised LCAT function is associated with increased atherosclerosis. Circulation. 2005;112:879-884.
64. O K, Hill JS, Wang X, Pritchard PH. Recombinant lecithin:cholesterol acyltransferase containing a Thr123-Ile mutation esterifes cholesterol in low density lipoprotein but not in high density lipoprotein. J Lipid Res. 1993;34:81-88.
65. Haase CL, Tybjærg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54, 500 individuals. J Clin Endocrinol Metab. 2012;97:E248-E256.
66. Sakai N, Vaisman BL, Koch CA, Hoyt RF Jr, Meyn SM, Talley GD, Paiz JA, Brewer HB Jr, Santamarina-Fojo S.Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT)gene. J Biol Chem. 1997;272:7506-7510.
67. Furbee JW Jr, Sawyer JK, Parks JS. Lecithin:cholesterol acyltrans-ferase defciency increases atherosclerosis in the low density lipo-protein receptor and apolipoprotein E knockout mice. J Biol Chem. 2002;277:3511-3519.
68. Mehlum A, Muri M, Hagve TA, Solberg LA, Prydz H. Mice overexpress-ing human lecithin: cholesterol acyltransferase are not protected against diet-induced atherosclerosis. APMIS. 1997;105:861-868.
69. Bérard AM, Föger B, Remaley A, Shamburek R, Vaisman BL, Talley G, Paigen B, Hoyt RF Jr, Marcovina S, Brewer HB Jr, Santamarina-Fojo S. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med. 1997;3:744-749.
70. Lambert G, Sakai N, Vaisman BL, et al. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-defcient mice. J Biol Chem. 2001;276:15090-15098.
71. Mertens A, Verhamme P, Bielicki JK, Phillips MC, Quarck R, Verreth W, Stengel D, Ninio E, Navab M, Mackness B, Mackness M, Holvoet P. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation. 2003;107:1640-1646.
72. Tall AR, Breslow JL, Rubin EM. Genetic disorders affecting plasma high-density lipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease (OMMBID). New York, NY: McGraw-Hill; 2001:2915-2936.
73. Isaacs A, Sayed-Tabatabaei FA, Njajou OT, Witteman JC, van Duijn CM. The-514 C-T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis. J Clin Endocrinol Metab. 2004;89:3858-3863.
74. Isaacs A, Aulchenko YS, Hofman A, Sijbrands EJ, Sayed-Tabatabaei FA, Klungel OH, Maitland-van der Zee AH, Stricker BH, Oostra BA, Witteman JC, van Duijn CM. Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum high-density lipoprotein cholesterol levels. J Clin Endocrinol Metab. 2007;92:2680-2687.
75. Mezdour H, Jones R, Dengremont C, Castro G, Maeda N. Hepatic li-pase defciency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-defcient mice. J Biol Chem. 1997;272:13570-13575.
76. Tang NP, Wang LS, Yang L, Zhou B, Gu HJ, Sun QM, Cong RH, Zhu HJ, Wang B. Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population. J Lipid Res. 2008;49:369-375.
77. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40:189-197.
78. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41:56-65.
79. Ishida T, Choi S, Kundu RK, Hirata K, Rubin EM, Cooper AD, Quertermous T. Endothelial lipase is a major determinant of HDL level. J Clin Invest. 2003;111:347-355.
80. Ishida T, Choi SY, Kundu RK, Spin J, Yamashita T, Hirata K, Kojima Y, Yokoyama M, Cooper AD, Quertermous T. Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-defcient mice. J Biol Chem. 2004;279:45085-45092.
81. Qiu G, Ho AC, Yu W, Hill JS. Suppression of endothelial or lipoprotein lipase in THP-1 macrophages attenuates proinfammatory cytokine secretion. J Lipid Res. 2007;48:385-394.
82. Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K, South V, Amin D, Perrone M, Rader DJ. A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet. 1999;21:424-428.
83. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 1999;99:2901-2907.
84. Kastelein JJ, Groenemeyer BE, Hallman DM, Henderson H, Reymer PW, Gagné SE, Jansen H, Seidell JC, Kromhout D, Jukema JW, Bruschke AV, Boerwinkle E, Hayden MR. The Asn9 variant of lipoprotein lipase is associated with the-93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group. Clin Genet. 1998;53:27-33.
85. Reymer PW, Gagné E, Groenemeyer BE, Zhang H, Forsyth I, Jansen H, Seidell JC, Kromhout D, Lie KE, Kastelein J. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat Genet. 1995;10:28-34.
86. Weinstock PH, Bisgaier CL, Aalto-Setälä K, Radner H, Ramakrishnan R, Levak-Frank S, Essenburg AD, Zechner R, Breslow JL. Severe hypertri-glyceridemia, reduced high density lipoprotein, and neonatal death in li-poprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J Clin Invest. 1995;96:2555-2568.
87. Gonzales AM, Orlando RA. Role of adipocyte-derived lipoprotein lipase in adipocyte hypertrophy. Nutr Metab (Lond). 2007;4:22.
88. Blattmann P, Schuberth C, Pepperkok R, Runz H. RNAi-based functional profling of loci from blood lipid genome-wide association studies identifes genes with cholesterol-regulatory function. PLoS Genet. 2013;9:e1003338.
89. Vergeer M, Boekholdt SM, Sandhu MS, et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation. 2010;122:470-477.
90. Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, Tall AR. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest. 1999;103:907-914.
91. Liu R, Iqbal J, Yeang C, Wang DQ, Hussain MM, Jiang XC. Phospholipid transfer protein-defcient mice absorb less cholesterol. Arterioscler Thromb Vasc Biol. 2007;27:2014-2021.
92. Albers JJ, Tu AY, Paigen B, Chen H, Cheung MC, Marcovina SM. Transgenic mice expressing human phospholipid transfer protein have increased HDL/non-HDL cholesterol ratio. Int J Clin Lab Res. 1996;26:262-267.
93. van Haperen R, van Tol A, van Gent T, Scheek L, Visser P, van der Kamp A, Grosveld F, de Crom R. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem. 2002;277:48938-48943.
94. Moerland M, Samyn H, van Gent T, van Haperen R, Dallinga-Thie G, Grosveld F, van Tol A, de Crom R. Acute elevation of plasma PLTP activity strongly increases pre-existing atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:1277-1282.
95. Brunham LR, Tietjen I, Bochem AE, Singaraja RR, Franchini PL, Radomski C, Mattice M, Legendre A, Hovingh GK, Kastelein JJ, Hayden MR. Novel mutations in scavenger receptor BI associated with high HDL cholesterol in humans. Clin Genet. 2011;79:575-581.
96. Chadwick AC, Sahoo D. Functional characterization of newly-discovered mutations in human SR-BI. PLoS One. 2012;7:e45660.
97. Vergeer M, Korporaal SJ, Franssen R, Meurs I, Out R, Hovingh GK, Hoekstra M, Sierts JA, Dallinga-Thie GM, Motazacker MM, Holleboom AG, Van Berkel TJ, Kastelein JJ, Van Eck M, Kuivenhoven JA. Genetic variant of the scavenger receptor BI in humans. N Engl J Med. 2011;364:136-145.
98. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA. 1997;94:12610-12615.
99. Huby T, Doucet C, Dachet C, Ouzilleau B, Ueda Y, Afzal V, Rubin E, Chapman MJ, Lesnik P. Knockdown expression and hepatic defciency reveal an atheroprotective role for SR-BI in liver and peripheral tissues. J Clin Invest. 2006;116:2767-2776.
100. Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM, Rosenberg RD, Schrenzel M, Krieger M. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-defcient mice. Circ Res. 2002;90:270-276.
101. Cai L, Eckhardt ER, Shi W, Zhao Z, Nasser M, de Villiers WJ, van der Westhuyzen DR. Scavenger receptor class B type I reduces cholesterol absorption in cultured enterocyte CaCo-2 cells. J Lipid Res. 2004;45:253-262.
102. Ueda Y, Royer L, Gong E, Zhang J, Cooper PN, Francone O, Rubin EM. Lower plasma levels and accelerated clearance of high density lipopro-tein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J Biol Chem. 1999;274:7165-7171.
103. Arai T, Wang N, Bezouevski M, Welch C, Tall AR. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-defcient mice expressing the scavenger receptor BI transgene. J Biol Chem. 1999;274:2366-2371.
104. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2005;5:1431-1445.
105. Qasim A, Rader DJ. Human genetics of variation in high-density lipopro-tein cholesterol. Curr Atheroscler Rep. 2006;8:198-205.
106. Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet. 2004;5:189-218.
107. Pietiläinen KH, Söderlund S, Rissanen A, Nakanishi S, Jauhiainen M, Taskinen MR, Kaprio J. HDL subspecies in young adult twins: heritability and impact of overweight. Obesity (Silver Spring). 2009;17:1208-1214.
108. Reddy MV, Iatan I, Weissglas-Volkov D, Nikkola E, Haas BE, Juvonen M, Ruel I, Ruel MJ, Sinsheimer JS, Genest J, Pajukanta P. Exome sequencing identifes 2 rare variants for low high-density lipoprotein cholesterol in an extended family. Circ Cardiovasc Genet. 2012;5:538-546.
109. Motazacker MM, Peter J, Treskes M, Shoulders CC, Kuivenhoven JA, Hovingh GK. Evidence of a polygenic origin of extreme high-density lipoprotein cholesterol levels. Arterioscler Thromb Vasc Biol. 2013;33:1521-1528.
110. Morrison AC, Voorman A, Johnson AD, et al; Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) Consortium. Whole-genome sequence-based analysis of high-density lipoprotein cholesterol. Nat Genet. 2013;45:899-901.
111. Ross CJ, Twisk J, Meulenberg JM, Liu G, van den Oever K, Moraal E, Hermens WT, Rip J, Kastelein JJ, Kuivenhoven JA, Hayden MR. Long-term correction of murine lipoprotein lipase defciency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) benefcial mutation. Hum Gene Ther. 2004;15:906-919.
112. de Backer G, de Bacquer D, Kornitzer M. Epidemiological aspects of high density lipoprotein cholesterol. Atherosclerosis. 1998;137(Suppl):S1-S6.
113. Solhpour A, Parkhideh S, Sarrafzadegan N, Asgary S, Williams K, Jungner I, Aastveit A, Walldius G, Sniderman A. Levels of lipids and apolipoproteins in three cultures. Atherosclerosis. 2009;207:200-207.
114. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298:786-798.
115. Tsimihodimos V, Gazi I, Filippatos T, Kostapanos M, Lagos K, Kostara C, Tellis CC, Elisaf M, Tselepis AD. Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia. Atherosclerosis. 2010;208:506-511.
116. Rashid S, Genest J. Effect of obesity on high-density lipoprotein metabolism. Obesity (Silver Spring). 2007;15:2875-2888.
117. De Oliveira E Silva ER, Foster D, McGee Harper M, Seidman CE, Smith JD, Breslow JL, Brinton EA. Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II. Circulation. 2000;102:2347-2352.
118. Gossett LK, Johnson HM, Piper ME, Fiore MC, Baker TB, Stein JH. Smoking intensity and lipoprotein abnormalities in active smokers. J Clin Lipidol. 2009;3:372-378.
119. Etogo-Asse FE, Atogo-Asse FE, Vincent RP, Hughes SA, Auzinger G, Le Roux CW, Wendon J, Bernal W. High density lipoprotein in patients with liver failure; relation to sepsis, adrenal function and outcome of illness. Liver Int. 2012;32:128-136.
120. Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol. 2010;55:2846-2854.
121. Singh-Manoux A, Gimeno D, Kivimaki M, Brunner E, Marmot MG. Low HDL cholesterol is a risk factor for defcit and decline in memory in midlife: the Whitehall II study. Arterioscler Thromb Vasc Biol. 2008;28:1556-1562.
122. Gordon DJ, Probstfeld JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8-15.
123. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
124. Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. Am J Med. 1951;11:480-493.
125. Rader DJ, Tall AR. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18:1344-1346.
126. Ng DS, Wong NC, Hegele RA. HDL-is it too big to fail? Nat Rev Endocrinol. 2013;9:308-312.
127. Ng DS, Leiter LA, Vezina C, Connelly PW, Hegele RA. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I defciency in a family with analphalipoproteinemia. J Clin Invest. 1994;93:223-229.
128. Matsunaga T, Hiasa Y, Yanagi H, Maeda T, Hattori N, Yamakawa K, Yamanouchi Y, Tanaka I, Obara T, Hamaguchi H. Apolipoprotein A-I de-fciency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene. Proc Natl Acad Sci USA. 1991;88:2793-2797.
129. Dastani Z, Dangoisse C, Boucher B, Desbiens K, Krimbou L, Dufour R, Hegele RA, Pajukanta P, Engert JC, Genest J, Marcil M. A novel nonsense apolipoprotein A-I mutation (apoA-I(E136X)) causes low HDL cholesterol in French Canadians. Atherosclerosis. 2006;185:127-136.
130. Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M, Johansson J, Salvetti M, Monteduro C, Zulli R, Muiesan ML, Agabiti-Rosei E. Cardiovascular status of carriers of the apolipopro-tein A-I(Milano) mutant: the Limone sul Garda study. Circulation. 2001;103:1949-1954.
131. Chiesa G, Sirtori CR. Apolipoprotein A-I(Milano): current perspectives. Curr Opin Lipidol. 2003;14:159-163.
132. Bruckert E, von Eckardstein A, Funke H, Beucler I, Wiebusch H, Turpin G, Assmann G. The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-IMilano. Atherosclerosis. 1997;128:121-128.
133. Holleboom AG, Duivenvoorden R, van den Bogaard B, de Groot E, Nederveen AJ, Lameris JS, Hutten BA, Kastelein JJ, Kuivenhoven JA, Stroes ES. Patients with low plasma high density lipoprotein-cholesterol due to mutations in the gene encoding for lecithin: cholesterol acyl transferase have increased atherosclerosis: a 3.0 Tesla MRI Study. Circulation. 2010;122:A17773.
134. Calabresi L, Baldassarre D, Castelnuovo S, et al. Functional lecithin: cholesterol acyltransferase is not required for effcient atheroprotection in humans. Circulation. 2009;120:628-635.
135. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein defciency. Nat Genet. 1999;22:336-345.
136. Hovingh GK, Kuivenhoven JA, Bisoendial RJ, Groen AK, van Dam M, van Tol A, Wellington C, Hayden MR, Smelt AH, Kastelein JJ. HDL de-fciency and atherosclerosis: lessons from Tangier disease. J Intern Med. 2004;255:299-301.
137. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234-1238.
138. Hirano K, Yamashita S, Sakai N, Arai T, Yoshida Y, Nozaki S, Kameda-Takemura K, Matsuzawa Y. Molecular defect and atherogenic-ity in cholesteryl ester transfer protein defciency. Ann N Y Acad Sci. 1995;748:599-602.
139. Cohen JC, Vega GL, Grundy SM. Hepatic lipase: new insights from genetic and metabolic studies. Curr Opin Lipidol. 1999;10:259-267.
140. Holleboom AG, Vergeer M, Hovingh GK, Kastelein JJ, Kuivenhoven JA. The value of HDL genetics. Curr Opin Lipidol. 2008;19:385-394.
141. van Acker BA, Botma GJ, Zwinderman AH, Kuivenhoven JA, Dallinga-Thie GM, Sijbrands EJ, Boer JM, Seidell JC, Jukema JW, Kastelein JJ, Jansen H, Verhoeven AJ; REGRESS Study Group. High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants. Atherosclerosis. 2008;200:161-167.
142. Johannsen TH, Kamstrup PR, Andersen RV, Jensen GB, Sillesen H, Tybjaerg-Hansen A, Nordestgaard BG. Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J Clin Endocrinol Metab. 2009;94:1264-1273.
143. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science. 2004;305:869-872.
144. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest. 2004;114:1343-1353.
145. Jensen MK, Rimm EB, Mukamal KJ, Edmondson AC, Rader DJ, Vogel U, Tjønneland A, Sørensen TI, Schmidt EB, Overvad K. The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. Eur Heart J. 2009;30:1584-1589.
146. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of isch-emic heart disease: The Copenhagen City Heart Study. Circulation. 2000;102:2197-2203.
147. Hingorani A, Humphries S. Nature's randomised trials. Lancet. 2005;366:1906-1908.
148. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572-580.
149. Ansell BJ, Fonarow GC, Fogelman AM. High-density lipoprotein: is it always atheroprotective? Curr Atheroscler Rep. 2006;8:405-411.
150. van de Sluis B, Kuivenhoven JA. News on the genetics of lipopro-tein metabolism and cardiovascular disease. Curr Opin Lipidol. 2013;24:185-186.
151. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006;116:3090-3100.
152. Zannis VI, Karathanasis SK, Keutmann HT, Goldberger G, Breslow JL. Intracellular and extracellular processing of human apolipoprotein A-I: secreted apolipoprotein A-I isoprotein 2 is a propeptide. Proc Natl Acad Sci USA. 1983;80:2574-2578.
153. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med (Berl). 2006;84:276-294.
154. Chau P, Fielding PE, Fielding CJ. Bone morphogenetic protein-1 (BMP-1) cleaves human proapolipoprotein A1 and regulates its activation for lipid binding. Biochemistry. 2007;46:8445-8450.
155. Zhu J, Gardner J, Pullinger CR, Kane JP, Thompson JF, Francone OL. Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1. J Lipid Res. 2009;50:1330-1339.
156. Zannis VI, Koukos G, Drosatos K, Vezeridis A, Zanni EE, Kypreos KE, Chroni A. Discrete roles of apoA-I and apoE in the biogenesis of HDL species: lessons learned from gene transfer studies in different mouse models. Ann Med. 2008;40(Suppl 1):14-28.
157. The Human Gene Mutation Database, HGMD Professional®, version 2012.4. http://www.hgmd.cf.ac.uk/ac/index.php. Accessed March 20, 2013.
158. Funke H. Genetic determinants of high density lipoprotein levels. Curr Opin Lipidol. 1997;8:189-196.
159. Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. J Lipid Res. 2010;51:2032-2057.
160. von Eckardstein A. Differential diagnosis of familial high density lipo-protein defciency syndromes. Atherosclerosis. 2006;186:231-239.
161. Bodzioch M, Orso E, Klucken J, et al. The gene encoding ATP binding cassette transporter 1 is mutated in Tangier disease. Nat Genet. 1999;22:347-351.
162. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denèfe P, Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22:352-355.
163. Tang C, Oram JF. The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetes. Biochim Biophys Acta. 2009;1791:563-572.
164. Assmann G, von Eckardstein A, Brewer HB Jr. Familial high density lipoprotein defciency. Tangier Disease. In: Scriver CR, Beaud AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 1995:2053.
165. Fredrickson DS, Gotto AM, Levy RI. Familial lipoprotein defciency. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 1972:493.
166. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest. 2005;115:1333-1342.
167. Mulya A, Seo J, Brown AL, Gebre AK, Boudyguina E, Shelness GS, Parks JS. Apolipoprotein M expression increases the size of nascent pre beta HDL formed by ATP binding cassette transporter A1. J Lipid Res. 2010;51:514-524.
168. Niu N, Zhu X, Liu Y, Du T, Wang X, Chen D, Sun B, Gu HF, Liu Y. Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (apoM) confer the susceptibility to development of type 2 diabetes in Han Chinese. Diabetes Metab Res Rev. 2007;23:21-25.
169. Zhou JW, Tsui SK, Ng MC, Geng H, Li SK, So WY, Ma RC, Wang Y, Tao Q, Chen ZY, Chan JC, Ho YY. Apolipoprotein M gene (APOM) polymorphism modifes metabolic and disease traits in type 2 diabetes. PLoS One. 2011;6:e17324.
170. Arkensteijn BW, Berbée JF, Rensen PC, Nielsen LB, Christoffersen C. The apolipoprotein m-sphingosine-1-phosphate axis: biological relevance in lipoprotein metabolism, lipid disorders and atherosclerosis. Int J Mol Sci. 2013;14:4419-4431.
171. Wilkerson BA, Grass GD, Wing SB, Argraves WS, Argraves KM. Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endo-thelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, traffcking, and signaling of S1P1. J Biol Chem. 2012;287:44645-44653.
172. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, Cyster JG, Coughlin SR. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316:295-298.
173. Karuna R, Park R, Othman A, Holleboom AG, Motazacker MM, Sutter I, Kuivenhoven JA, Rohrer L, Matile H, Hornemann T, Stoffel M, Rentsch KM, von Eckardstein A. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis. 2011;219:855-863.
174. Barter P, Kastelein J, Nunn A, Hobbs R; Future Forum Editorial Board. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis. 2003;168:195-211.
175. Norum KR, Gjone E. Familial plasma lecithin:cholesterol acyltransfer-ase defciency. Biochemical study of a new inborn error of metabolism. Scand J Clin Lab Invest. 1967;20:231-243.
176. Carlson LA, Philipson B. Fish-eye disease. A new familial condition with massive corneal opacities and dyslipoproteinaemia. Lancet. 1979;2:922-924.
177. Ng DS. Insight into the role of LCAT from mouse models. Rev Endocr Metab Disord. 2004;5:311-318.
178. Rader DJ, Ikewaki K, Duverger N, Schmidt H, Pritchard H, Frohlich J, Clerc M, Dumon MF, Fairwell T, Zech L. Markedly accelerated catabo-lism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase defciency and fsh-eye disease. J Clin Invest. 1994;93:321-330.
179. Norum KR, Gjone E. Familial serum-cholesterol esterifcation failure. A new inborn error of metabolism. Biochim Biophys Acta. 1967;144:698-700.
180. Ng DS, Francone OL, Forte TM, Zhang J, Haghpassand M, Rubin EM. Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I. J Biol Chem. 1997;272:15777-15781.
181. Santamarina-Fojo S, Hoeg JM, Assmann G, Brewer HB Jr, eds. The Online Metabolic and Molecular Bases of Inherited Diseases (OMMBID). Lecithin Cholesterol Acyltransferase Defciency and Fish Eye Disease. New York, NY: McGraw-Hill; 2011:24.
182. Francone OL, Gong EL, Ng DS, Fielding CJ, Rubin EM. Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein all on plasma lipo-protein cholesterol metabolism. J Clin Invest. 1995;96:1440-1448.
183. Jacobs RL, Devlin C, Tabas I, Vance DE. Targeted deletion of hepatic CTP:phosphocholine cytidylyltransferase alpha in mice decreases plasma high density and very low density lipoproteins. J Biol Chem. 2004;279:47402-47410.
184. Karim M, Jackson P, Jackowski S. Gene structure, expression and identi-fcation of a new CTP:phosphocholine cytidylyltransferase beta isoform. Biochim Biophys Acta. 2003;1633:1-12.
185. Kennedy EP, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phospholipides. J Biol Chem. 1956;222:193-214.
186. Rye KA, Clay MA, Barter PJ. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis. 1999;145:227-238.
187. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, Marcel YL, Milne RW, Koizumi J, Mabuchi H. Molecular basis of lipid transfer protein defciency in a family with increased high-density lipo-proteins. Nature. 1989;342:448-451.
188. van der Steeg WA, Hovingh GK, Klerkx AH, Hutten BA, Nootenboom IC, Levels JH, van Tol A, Dallinga-Thie GM, Zwinderman AH, Kastelein JJ, Kuivenhoven JA. Cholesteryl ester transfer protein and hyperalphali-poproteinemia in Caucasians. J Lipid Res. 2007;48:674-682.
189. Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, Tybjærg-Hansen A. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol. 2012;60:2041-2048.
190. Agellon LB, Walsh A, Hayek T, Moulin P, Jiang XC, Shelanski SA, Breslow JL, Tall AR. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem. 1991;266:10796-10801.
191. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol. 1999;19:1105-1110.
192. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008;23:370-378.
193. Lusa S, Jauhiainen M, Metso J, Somerharju P, Ehnholm C. The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem J. 1996;313(Pt 1):275-282.
194. Jiang X, Francone OL, Bruce C, Milne R, Mar J, Walsh A, Breslow JL, Tall AR. Increased prebeta-high density lipoprotein, apolipopro-tein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest. 1996;98:2373-2380.
195. Engler MB, Pullinger CR, Malloy MJ, Natanzon Y, Kulkarni MV, Song J, Eng C, Huuskonen J, Rivera C, Poon A, Bensley M, Sehnert A, Zellner C, Kane J, Aouizerat BE. Genetic variation in phospholipid transfer protein modulates lipoprotein profles in hyperalphalipoproteinemia. Metabolism. 2008;57:1719-1724.
196. Brunzell JD, Deeb SS, eds. The Online Metabolic and Molecular Bases of Inherited Diseases (OMMBID). Familial Lipoprotein Lipase Defciency, Apo C-II Defciency, and Hepatic Lipase Defciency. New York, NY: McGraw-Hill; 2011: 40.
197. Santamarina-Fojo S, González-Navarro H, Freeman L, Wagner E, Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol. 2004;24:1750-1754.
198. Klos KL, Kullo IJ. Genetic determinants of HDL: monogenic disorders and contributions to variation. Curr Opin Cardiol. 2007;22:344-351.
199. Sviridov D, Nestel PJ. Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol. 2007;18:157-163.
200. Hirata K, Dichek HL, Cioff JA, Choi SY, Leeper NJ, Quintana L, Kronmal GS, Cooper AD, Quertermous T. Cloning of a unique lipase from endothelial cells extends the lipase gene family. J Biol Chem. 1999;274:14170-14175.
201. Jin W, Millar JS, Broedl U, Glick JM, Rader DJ. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest. 2003;111:357-362.
202. Fuki IV, Blanchard N, Jin W, Marchadier DH, Millar JS, Glick JM, Rader DJ. Endogenously produced endothelial lipase enhances binding and cellular processing of plasma lipoproteins via heparan sulfate proteoglycan-mediated pathway. J Biol Chem. 2003;278:34331-34338.
203. Willer CJ, Sanna S, Jackson AU, et al. Newly identifed loci that infu-ence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161-169.
204. Edmondson AC, Brown RJ, Kathiresan S, et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest. 2009;119:1042-1050.
205. Brown RJ, Edmondson AC, Griffon N, Hill TB, Fuki IV, Badellino KO, Li M, Wolfe ML, Reilly MP, Rader DJ. A naturally occurring variant of endothelial lipase associated with elevated HDL exhibits impaired synthesis. J Lipid Res. 2009;50:1910-1916.
206. Singaraja RR, Sivapalaratnam S, Hovingh K, et al. The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans. Circ Cardiovasc Genet. 2013;6:54-62.
207. Murakami M, Kudo I. New phospholipase A(2) isozymes with a potential role in atherosclerosis. Curr Opin Lipidol. 2003;14:431-436.
208. Webb NR, Bostrom MA, Szilvassy SJ, van der Westhuyzen DR, Daugherty A, de Beer FC. Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-defcient mice. Arterioscler Thromb Vasc Biol. 2003;23:263-268.
209. Tietge UJ, Maugeais C, Cain W, Grass D, Glick JM, de Beer FC, Rader DJ. Overexpression of secretory phospholipase A(2) causes rapid catab-olism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem. 2000;275:10077-10084.
210. Exeter HJ, Folkersen L, Palmen J, Franco-Cereceda A, Cooper JA, Kalea AZ, Hooft FV, Eriksson P, Humphries SE, Talmud PJ. Functional analysis of two PLA2G2A variants associated with secretory phospholipase A2-IIA levels. PLoS One. 2012;7:e41139.
211. Magill P, Rao SN, Miller NE, Nicoll A, Brunzell J, St Hilaire J, Lewis B. Relationships between the metabolism of high-density and very-low-density lipoproteins in man: studies of apolipoprotein kinetics and adipose tissue lipoprotein lipase activity. Eur J Clin Invest. 1982;12:113-120.
212. Tsutsumi K, Inoue Y, Shima A, Iwasaki K, Kawamura M, Murase T. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J Clin Invest. 1993;92:411-417.
213. Aulchenko YS, Ripatti S, Lindqvist I, et al; ENGAGE Consortium. Loci infuencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet. 2009;41:47-55.
214. Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism. 2012;61:906-921.
215. Fojo SS, Stalenhoef AF, Marr K, Gregg RE, Ross RS, Brewer HB Jr. A deletion mutation in the ApoC-II gene (ApoC-II Nijmegen) of a patient with a defciency of apolipoprotein C-II. J Biol Chem. 1988;263:17913-17916.
216. Fellin R, Baggio G, Poli A, Augustin J, Baiocchi MR, Baldo G, Sinigaglia M, Greten H, Crepaldi G. Familial lipoprotein lipase and apolipoprotein C-II defciency. Lipoprotein and apoprotein analysis, adipose tissue and hepatic lipoprotein lipase levels in seven patients and their frst degree relatives. Atherosclerosis. 1983;49:55-68.
217. Tian L, Xu Y, Fu M, Jia L, Yang Y. Infuence of apolipoproteinCII concentrations on HDL subclass distribution. J Atheroscler Thromb. 2009;16:611-620.
218. O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, Schultze AE, Konrad RJ. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipopro-teins. Clin Chem. 2005;51:351-359.
219. Calandra S, Priore Oliva C, Tarugi P, Bertolini S. APOA5 and triglyc-eride metabolism, lesson from human APOA5 defciency. Curr Opin Lipidol. 2006;17:122-127.
220. Ioka RX, Kang MJ, Kamiyama S, Kim DH, Magoori K, Kamataki A, Ito Y, Takei YA, Sasaki M, Suzuki T, Sasano H, Takahashi S, Sakai J, Fujino T, Yamamoto TT. Expression cloning and characterization of a novel glycosylphosphatidylinositol- anchored high density lipoprotein-binding protein, GPI-HBP1. J Biol Chem. 2003;278:7344-7349.
221. Beigneux A P, Davies BS, Gin P, et al. Glycosylphosphatidylinositol- anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 2007;5:279-291.
222. Davies BS, Beigneux AP, Barnes RH 2nd, Tu Y, Gin P, Weinstein MM, Nobumori C, Nyrén R, Goldberg I, Olivecrona G, Bensadoun A, Young SG, Fong LG. GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab. 2010;12:42-52.
223. Coca-Prieto I, Kroupa O, Gonzalez-Santos P, Magne J, Olivecrona G, Ehrenborg E, Valdivielso P. Childhood-onset chylomicronaemia with reduced plasma lipoprotein lipase activity and mass: identifcation of a novel GPIHBP1 mutation. J Intern Med. 2011;270:224-228.
224. Young SG, Davies BS, Voss CV, Gin P, Weinstein MM, Tontonoz P, Reue K, Bensadoun A, Fong LG, Beigneux AP. GPIHBP1, an endothelial cell transporter for lipoprotein lipase. J Lipid Res. 2011;52:1869-1884.
225. Rios JJ, Shastry S, Jasso J, Hauser N, Garg A, Bensadoun A, Cohen JC, Hobbs HH. Deletion of GPIHBP1 causing severe chylomicronemia. J Inherit Metab Dis. 2012;35:531-540.
226. Yamamoto H, Onishi M, Miyamoto N, Oki R, Ueda H, Ishigami M, Hiraoka H, Matsuzawa Y, Kihara S. Novel combined GPIHBP1 mutations in a patient with hypertriglyceridemia associated with CAD. J Atheroscler Thromb. 2013;20:777-784.
227. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 1990;249:790-793.
228. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceride-mia and protection from postprandial hypertriglyceridemia. J Biol Chem. 1994;269:23610-23616.
229. Wandall HH, Hassan H, Mirgorodskaya E, Kristensen AK, Roepstorff P, Bennett EP, Nielsen PA, Hollingsworth MA, Burchell J, Taylor-Papadimitriou J, Clausen H. Substrate specifcities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1,-T2, and-T3. J Biol Chem. 1997;272:23503-23514.
230. Desai U, Lee EC, Chung K, et al. Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc Natl Acad Sci USA. 2007;104:11766-11771.
231. Köster A, Chao YB, Mosior M, Ford A, Gonzalez-DeWhitt PA, Hale JE, Li D, Qiu Y, Fraser CC, Yang DD, Heuer JG, Jaskunas SR, Eacho P. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology. 2005;146:4943-4950.
232. Ono M, Shimizugawa T, Shimamura M, Yoshida K, Noji-Sakikawa C, Ando Y, Koishi R, Furukawa H. Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J Biol Chem. 2003;278:41804-41809.
233. Shimamura M, Matsuda M, Yasumo H, et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial li-pase. Arterioscler Thromb Vasc Biol. 2007;27:366-372.
234. Jin W, Wang X, Millar JS, Quertermous T, Rothblat GH, Glick JM, Rader DJ. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab. 2007;6:129-136.
235. Romeo S, Pennacchio LA, Fu Y, Boerwinkle E, Tybjaerg-Hansen A, Hobbs HH, Cohen JC. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet. 2007;39:513-516.
236. Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, Hobbs HH, Cohen JC. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest. 2009;119:70-79.
237. Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363:2220-2227.
238. Kiss-Toth E, Bagstaff SM, Sung HY, Jozsa V, Dempsey C, Caunt JC, Oxley KM, Wyllie DH, Polgar T, Harte M, O'neill LA, Qwarnstrom EE, Dower SK. Human tribbles, a protein family controlling mitogen-activated protein kinase cascades. J Biol Chem. 2004;279:42703-42708.
239. Sung HY, Guan H, Czibula A, King AR, Eder K, Heath E, Suvarna SK, Dower SK, Wilson AG, Francis SE, Crossman DC, Kiss-Toth E. Human tribbles-1 controls proliferation and chemotaxis of smooth muscle cells via MAPK signaling pathways. J Biol Chem. 2007;282:18379-18387.
240. Burkhardt R, Toh SA, Lagor WR, Birkeland A, Levin M, Li X, Robblee M, Fedorov VD, Yamamoto M, Satoh T, Akira S, Kathiresan S, Breslow JL, Rader DJ. Trib1 is a lipid-and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice. J Clin Invest. 2010;120:4410-4414.
241. Bishop JR, Stanford KI, Esko JD. Heparan sulfate proteoglycans and triglyceride-rich lipoprotein metabolism. Curr Opin Lipidol. 2008;19:307-313.
242. Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role for pro-teoglycans in trapping, transferring, and internalizing. J Clin Invest. 2007;117:94-98.
243. Hodoglugil U, Williamson DW, Yu Y, Farrer LA, Mahley RW. Glucuronic acid epimerase is associated with plasma triglyceride and high-density li-poprotein cholesterol levels in Turks. Ann Hum Genet. 2011;75:398-417.
244. Oram JF, Lawn RM, Garvin MR, Wade DP. ABCA1 is the cAMP-in-ducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem. 2000;275:34508-34511.
245. Ji Y, Jian B, Wang N, Sun Y, Moya ML, Phillips MC, Rothblat GH, Swaney JB, Tall AR. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol effux. J Biol Chem. 1997;272:20982-20985.
246. Klucken J, Büchler C, Orsó E, Kaminski WE, Porsch-Ozcürümez M, Liebisch G, Kapinsky M, Diederich W, Drobnik W, Dean M, Allikmets R, Schmitz G. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci USA. 2000;97:817-822.
247. Kusuhara H, Sugiyama Y. ATP-binding cassette, subfamily G (ABCG family). Pfugers Arch. 2007;453:735-744.
248. Wiersma H, Nijstad N, de Boer JF, Out R, Hogewerf W, Van Berkel TJ, Kuipers F, Tietge UJ. Lack of Abcg1 results in decreased plasma HDL cholesterol levels and increased biliary cholesterol secretion in mice fed a high cholesterol diet. Atherosclerosis. 2009;206:141-147.
249. Schou J, Frikke-Schmidt R, Kardassis D, Thymiakou E, Nordestgaard BG, Jensen G, Grande P, Tybjærg-Hansen A. Genetic variation in ABCG1 and risk of myocardial infarction and ischemic heart disease. Arterioscler Thromb Vasc Biol. 2012;32:506-515.
250. Jian B, de la Llera-Moya M, Ji Y, Wang N, Phillips MC, Swaney JB, Tall AR, Rothblat GH. Scavenger receptor class B type I as a mediator of cellular cholesterol effux to lipoproteins and phospholipid acceptors. J Biol Chem. 1998;273:5599-5606.
251. Hildebrand RB, Lammers B, Meurs I, et al. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI defciency. Arterioscler Thromb Vasc Biol. 2010;30:1439-1445.
252. Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 1997;387:414-417.
253. Azhar S, Reaven E. Scavenger receptor class BI and selective choles-teryl ester uptake: partners in the regulation of steroidogenesis. Mol Cell Endocrinol. 2002;195:1-26.
254. Azhar S, Leers-Sucheta S, Reaven E. Cholesterol uptake in adrenal and gonadal tissues: the SR-BI and 'selective' pathway connection. Front Biosci. 2003;8:s998-s1029.
255. Hoekstra M, Meurs I, Koenders M, Out R, Hildebrand RB, Kruijt JK, Van Eck M, Van Berkel TJ. Absence of HDL cholesteryl ester uptake in mice via SR-BI impairs an adequate adrenal glucocorticoid-mediated stress response to fasting. J Lipid Res. 2008;49:738-745.
256. Acton S, Osgood D, Donoghue M, Corella D, Pocovi M, Cenarro A, Mozas P, Keilty J, Squazzo S, Woolf EA, Ordovas JM. Association of polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population. Arterioscler Thromb Vasc Biol. 1999;19:1734-1743.
257. Osgood D, Corella D, Demissie S, Cupples LA, Wilson PW, Meigs JB, Schaefer EJ, Coltell O, Ordovas JM. Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the Framingham study. J Clin Endocrinol Metab. 2003;88:2869-2879.
258. Bochem AE, Holleboom AG, Romijn JA, Hoekstra M, Dallinga-Thie GM, Motazacker MM, Hovingh GK, Kuivenhoven JA, Stroes ES. High density lipoprotein as a source of cholesterol for adrenal steroido-genesis: a study in individuals with low plasma HDL-C. J Lipid Res. 2013;54:1698-1704.
259. Ridgway ND. Oxysterol-binding proteins. Subcell Biochem. 2010;51:159-182.
260. Raychaudhuri S, Prinz WA. The diverse functions of oxysterol-binding proteins. Annu Rev Cell Dev Biol. 2010;26:157-177.
261. Vihervaara T, Jansen M, Uronen RL, Ohsaki Y, Ikonen E, Olkkonen VM. Cytoplasmic oxysterol-binding proteins: sterol sensors or transporters? Chem Phys Lipids. 2011;164:443-450.
262. Yan D, Mäyränpää MI, Wong J, Perttilä J, Lehto M, Jauhiainen M, Kovanen PT, Ehnholm C, Brown AJ, Olkkonen VM. OSBP-related protein 8 (ORP8) suppresses ABCA1 expression and cholesterol effux from macrophages. J Biol Chem. 2008;283:332-340.
263. Vihervaara T, Käkelä R, Liebisch G, Tarasov K, Schmitz G, Olkkonen VM. Modifcation of the lipidome in RAW264.7 macrophage subjected to stable silencing of oxysterol-binding proteins. Biochimie. 2013;95:538-547.
264. Béaslas O, Metso J, Nissilä E, Laurila PP, Kaiharju E, Batchu KC, Kaipiainen L, Mäyränpää MI, Yan D, Gylling H, Jauhiainen M, Olkkonen VM. Osbpl8 defciency in mouse causes an elevation of high-density lipoproteins and gender-specifc alterations of lipid metabolism. PLoS One. 2013;8:e58856.
265. Ginsberg H, Grabowski GA, Gibson JC, Fagerstrom R, Goldblatt J, Gilbert HS, Desnick RJ. Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease. Clin Genet. 1984;26:109-116.
266. Morales LE. Gaucher's disease: a review. Ann Pharmacother. 1996;30:381-388.
267. Pocovi M, Cenarro A, Civeira F, Torralba MA, Perez-Calvo JI, Mozas P, Giraldo P, Giralt M, Myers RH, Cupples LA, Ordovas JM. Beta-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-alpha- lipoproteinaemia. Lancet. 1998;351:1919-1923.
268. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249-254.
269. Assmann G, Seedorf U, Acid lipase defciency: Wolman disease and cho-lesteryl ester storage disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:3551-3572.
270. Pisciotta L, Fresa R, Bellocchio A, Pino E, Guido V, Cantafora A, Di Rocco M, Calandra S, Bertolini S. Cholesteryl ester storage disease (CESD) due to novel mutations in the LIPA gene. Mol Genet Metab. 2009;97:143-148.
271. Mineo C, Shaul PW. Functions of scavenger receptor class B, type I in atherosclerosis. Curr Opin Lipidol. 2012;23:487-493.
272. Chan DC, Barrett PH, Ooi EM, Ji J, Chan DT, Watts GF. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. J Clin Endocrinol Metab. 2009;94:989-997.
273. Baragetti A, Norata GD, Sarcina C, Rastelli F, Grigore L, Garlaschelli K, Uboldi P, Baragetti I, Pozzi C, Catapano AL. High density lipopro-tein cholesterol levels are an independent predictor of the progression of chronic kidney disease. J Intern Med. 2013;274:252-262.
274. Moestrup SK, Nielsen LB. The role of the kidney in lipid metabolism. Curr Opin Lipidol. 2005;16:301-306.
275. Hammad SM, Barth JL, Knaak C, Argraves WS. Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J Biol Chem. 2000;275:12003-12008.
276. Christensen EI, Gburek J. Protein reabsorption in renal proximal tubule-function and dysfunction in kidney pathophysiology. Pediatr Nephrol. 2004;19:714-721.
277. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478:404-407.
278. Fu J, Wolfs MG, Deelen P, et al. Unraveling the regulatory mechanisms underlying tissue-dependent genetic variation of gene expression. PLoS Genet. 2012;8:e1002431.
279. Suhre K, Gieger C. Genetic variation in metabolic phenotypes: study designs and applications. Nat Rev Genet. 2012;13:759-769.